scholarly journals Impact of Penicillin Susceptibility on Medical Outcomes for Adult Patients with Bacteremic Pneumococcal Pneumonia

2000 ◽  
Vol 30 (3) ◽  
pp. 520-528 ◽  
Author(s):  
J. P. Metlay ◽  
J. Hofmann ◽  
M. S. Cetron ◽  
M. J. Fine ◽  
M. M. Farley ◽  
...  
2018 ◽  
Vol 2 (1) ◽  
Author(s):  
Jorge H. Gentile ◽  
Claudia Hernandez ◽  
Monica D. Sparo ◽  
Edgardo M. Rodriguez ◽  
Carolina Ceriani ◽  
...  

2014 ◽  
Vol 1 (2) ◽  
Author(s):  
Mathieu Blot ◽  
Delphine Croisier ◽  
André Péchinot ◽  
Ameline Vagner ◽  
Alain Putot ◽  
...  

Abstract Background.  Bacteremic pneumococcal pneumonia (BPP) is associated with high and early mortality. A simple procedure to predict mortality is crucial. Methods.  All adult patients with BPP admitted from 2005 through 2013 to the University Hospital of Dijon, France, were enrolled to study 30-day mortality and associated factors, particularly leukocyte counts. A simple leukocyte score was created by adding 1 point each for neutropenia (<1500 cells/mm3), lymphopenia (<400), and monocytopenia (<200). Results.  One hundred and ninety-two adult patients (mean age, 69 years; standard deviation [SD], 19 years) who had developed and were hospitalized for BPP (58% community-acquired) were included. The 30-day crude mortality rate was 21%. The mean Pneumonia Severity Index score was high at 127.3 (SD = 41.3). Among the 182 patients who had a white blood cell count, 34 (19%) had a high leukocyte score (≥2). Multivariate analysis revealed that mortality was significantly associated with a high leukocyte score (odds ratio, 6.28; 95% confidence interval, 2.35–16.78), a high respiratory rate, a low serum bicarbonate level, and an altered mental status (all P < .05). The leukocyte score was not significantly dependent on the previous state of immunosuppression, alcoholism, or viral coinfection, but it did correlate with an acute respiratory distress syndrome and a low serum bicarbonate level. Conclusions.  This new leukocyte score, in combination with the well known predictive factors, seems of interest in predicting the risk of death in BPP. A high score correlated with organ dysfunction and probably reflects the level of immunoparalysis. Its predictive value has to be confirmed in other cohorts.


2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S739-S739
Author(s):  
Allison McGeer

Abstract Background Herd immunity from pediatric pneumococcal conjugate vaccine (PCV) programs has resulted in substantial reductions in IPD due to PCV serotypes (ST). We assessed whether similar changes in ST distribution occur in non-bacteremic pneumococcal pneumonia (NBPP). Methods The Toronto Invasive Bacterial Diseases Network performs population-based surveillance for IPD and hospitalized, culture-confirmed NBPP in Toronto/Peel Region, Canada (Pop 4.5M). Patient data are collected by interview/chart review; illness associated with respiratory isolates is categorized using Musher criteria. Results Since 2002, 6627 episodes of IPD, and 7323 non-bacteremic episodes with a respiratory isolate of S. pneumoniae (2180 meeting modified Musher criteria for NBPP) have occurred in adults. Distributions of vaccine-type serotypes in IPD and NBPP pre-PCV7 (2002-2004), post-PCV7 (2006-2009) and late post-PCV13 (2014-2019) are shown in the Figure. There were no significant changes in distribution of vaccine serotype groups from 2014-2019 in IPD or NBPP. From 2014-2019, serotypes included in PCV13 and PCV20 were associated with 33% and 59% of IPD cases, and 29% and 49% of NBPP cases in adults.. Figure. distribution of serotype groups included in different pneumococcal vaccines in cases of IPD and non-bacteremic pneumonia Conclusion Eight years post routine infant PCV13 implementation, PCV13 type IPD and NBPP persists in adults. The distribution of vaccine-type strains is similar in IPD and NBPP; although non-vaccine-type strains are more common in NBPP. Disclosures Allison McGeer, MD, FRCPC, GlaxoSmithKline (Advisor or Review Panel member, Research Grant or Support)Merck (Advisor or Review Panel member, Research Grant or Support)Pfizer (Research Grant or Support)


2006 ◽  
Vol 12 (8) ◽  
pp. 1223-1230 ◽  
Author(s):  
Joshua P. Metlay ◽  
Neil O. Fishman ◽  
Marshall M. Joffe ◽  
Michael J. Kallan ◽  
Jesse L. Chittams ◽  
...  

Author(s):  
R. Dwyer ◽  
Å. Örtqvist ◽  
E. Aufwerber ◽  
B. Henriques Normark ◽  
T.J. Marrie ◽  
...  

Vaccine ◽  
2017 ◽  
Vol 35 (14) ◽  
pp. 1749-1757 ◽  
Author(s):  
Gertjan H.J. Wagenvoort ◽  
Elisabeth A.M. Sanders ◽  
Hester E. de Melker ◽  
Arie van der Ende ◽  
Bart J. Vlaminckx ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document